Formulation

Changing demands in drug development lead to new service combinations and models.

Bristol-Myers Squibb's fit-for-purpose mode for clinical-trial materials for early-stage development seeks to achieve a better way in resource allocation. This article is part of a special issue on API Development, Formulation, Synthesis and Manufacturing.

Week of Aug. 23, 2010: Company and People Notes: Quark and Novartis Form Agreement; Hospira CEO Retires; And More.

Two new reports describe the vaccine market's recent growth and predict future market expansions.

Eli Lilly Ends Semagacestat Program; Selecta Appoints CEO; And More.

Penwest and Endo to Merge; Watson Makes Senior Appointments; And More.

In a draft guidance published this week, the US Food and Drug Administration recommended that makers of transdermal and transmucosal drug-delivery systems use "an appropriate scientific approach" during product design, development, and manufacturing to minimize the amount of residual drug substance present at the end of the products' labeled use periods.

FDA Approves Flu Vaccines; Caraco Names COO; And More.

Industry's focus on cost cutting has led to a dangerous gap in training and knowledge.

Industry can meet its responsibility to society by considering innovative pricing and partnerships.

Pharmaceutical Technology talked to experts in siRNA-drug development to gain insight into the characteristics, processes, and challenges of this class of therapeutics.

As emerging markets become increasingly important for the pharmaceutical majors, companies are re-evaluating their outsourcing strategies. This article is part of the 2010 Outsourcing Resources special issue.

The authors describe recent market trends and indicate the likely future direction of the pharmaceutical and biopharmaceutical industries. This article is part of the 2010 Outsourcing Resources special issue.

Merck and Sinopharm Sign Agreement; Agilent Appoints CFO; And More.

Pfizer Ends Second Tanezumab Clinical Program; Catalent VP Joins USP Panel; And More.

Xcelience and Penn Form Joint Venture; Almac Appoints QA Director; And More.

Eli Lilly to Acquire Alnara Pharmaceuticals; Exelixis CEO Leaves for Biogen Idec; And More.

To continue innovating, the biopharmaceutical sector needs support from all levels.

The functionality and performance of three types of commercial superdisintegrants were evaluated in the application of orally disintegrating tablets.

Is now the time for multiparticulates to shine as a controlled-release solution?

Technical Note: The authors investigated the variables important for calcium-alginate formation as well as dissolution.

Excipient manufacturers expand their products, services, manufacturing capacity, and technology positions.

After a spate of industrial disasters, the public seeks greater oversight of corporations-so does FDA.

Pfizer Suspends Tanezumab Program; Actavis Appoints CEO; And More.

How can crystal engineering and pharma sciences be combined to enhance the clinical performance of drugs?

Company and People Notes: Valeant and Biovail to Merge; GPhA Names Interim Director; And More.

GSK Acquires Laboratorios Phoenix; Catalent Makes Executive Appointments; And More.

Thermo Fisher to Acquire Fermentas; Pfizer Names Head of R&D; And More.

Europe moves to place excipient GMP and GDP standards on the same level as active pharmaceutical ingredients.

Too much or too little control can actually lead to the same result.